Cepodem-O 10 Tablets

babies: it does not apply to babies. lactating mothers: it is unsafe during breastfeeding.
limited studies have shown evidence drugs may pass into breast milk and harm the baby. please consult your doctor.
pregnancy: it is unsafe in pregnancy. limited studies have shown harmful effects on developing babies.
please consult your doctor. driving: cefpodoxime proxetil and ofloxacin tablet may decrease alertness, affects vision and may cause dizziness and sleep.
do not drive if these symptoms occur. alcohol: avoid consumption of alcohol while taking cefpodoxime proxetil and ofloxacin tablet as it causes severe liver damage.
kidney: cefpodoxime proxetil and ofloxacin tablets should be used with caution in patients with kidney disease. dosage adjustment may be required.
please consult your doctor. liver: methotrexate tablets should be used with caution in patients with liver disease.
dosage adjustment may be required. please consult your doctor..

Nausea Vomiting Diarrhea Stomach pain Headache.

CEPODEM-O works by preventing the formation of the protective covering of bacteria which is essential for the survival of bacteria. potassium clavulanate is a beta-lactamase inhibitor that decreases resistance and increases the activity of cefpodoxime proxetil against bacteria..

If you miss a dose, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• CEPODEM-O is used to treat bacterial infections. • complete the course of treatment; stopping early may cause resistance.
• this can be taken with food and take plenty of fluids to avoid stomach upset. • stop taking this tablet and inform your doctor immediately if you develop a rash, swelling of the face, throat or tongue or breathing difficulties while taking it.
• do not use remaining medicine for treating any infection in the future. consult the doctor before taking any antibiotic..

• cefpodoxime proxetil + abacavir: concurrent use leads to decrease the excretion rate of abacavir • cefpodoxime proxetil + abciximab: concurrent use leads to decrease the therapeutic efficacy of abciximab • cefpodoxime proxetil + aceclofenac: concurrent use leads to increase the risk of severity of nephrotoxicity • ofloxacin + amantadin: concurrent use leads to increase the risk of severity qtc prolongation • ofloxacin + aminophylline: concurrent use leads to decrease the metabolism of aminophylline.